Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance - Wikidata - awgldk - TriplyDB

Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance

Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance

http://www.wikidata.org/entity/Q26866517

about

Three-dimensional lung tumor microenvironment modulates therapeutic compound responsiveness in vitro--implication for drug development Recent advances in understanding idiopathic pulmonary fibrosis Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment Pharmacogenetics and outcome with antipsychotic drugs Murine models of inflammatory bowel disease (IBD): challenges of modeling human disease Hands-on workshops as an effective means of learning advanced technologies including genomics, proteomics and bioinformatics Metadherin regulates proliferation and metastasis via actin cytoskeletal remodelling in non-small cell lung cancer QSAR based model for discriminating EGFR inhibitors and non-inhibitors using Random forest Expression pattern of FGFR2, Grb2 and Plcγ1 acts as a novel prognostic marker of recurrence recurrence-free survival in lung adenocarcinoma.Imaging biomarker roadmap for cancer studies Photoacoustic signal characterization of cancer treatment response: Correlation with changes in tumor oxygenation.Insights into cancer severity from biomolecular interaction mechanisms.Integrative analysis of longitudinal metabolomics data from a personal multi-omics profile Polypharmacology in Precision Oncology: Current Applications and Future Prospects MDP, a database linking drug response data to genomic information, identifies dasatinib and statins as a combinatorial strategy to inhibit YAP/TAZ in cancer cells Minimizing bias in target selection by exploiting multidisciplinary Big Data and the protein interactome.NOD-scidIl2rg (tm1Wjl) and NOD-Rag1 (null) Il2rg (tm1Wjl) : a model for stromal cell-tumor cell interaction for human colon cancer Molecular tumor board: the University of California-San Diego Moores Cancer Center experience.Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers.Quantitative network mapping of the human kinome interactome reveals new clues for rational kinase inhibitor discovery and individualized cancer therapy Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years Variable NF-κB pathway responses in colon cancer cells treated with chemotherapeutic drugs Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer Functional consequences of somatic mutations in cancer using protein pocket-based prioritization approach."Just caring": can we afford the ethical and economic costs of circumventing cancer drug resistance?Kinotypes: stable species- and individual-specific profiles of cellular kinase activity.Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures EPMA position paper in cancer: current overview and future perspectives.Molecular screening of cancer-derived exosomes by surface plasmon resonance spectroscopy.Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnostics The combinatorial approach of laser-captured microdissection and reverse transcription quantitative polymerase chain reaction accurately determines HER2 status in breast cancer.Precision wildlife medicine: applications of the human-centred precision medicine revolution to species conservation.Mining the Breast Cancer Proteome for Predictors of Drug Sensitivity.Cancer biomarker discovery using DNA aptamers.Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.Continuous quantification of HER2 expression by microfluidic precision immunofluorescence estimates HER2 gene amplification in breast cancer The current state of the art of quantitative phosphoproteomics and its applications to diabetes research Next-generation sequencing in NSCLC and melanoma patients: a cost and budget impact analysis.Meta-analysis for genome-wide association studies using case-control design: application and practice.A Microfluidic Immunostaining System Enables Quality Assured and Standardized Immunohistochemical Biomarker Analysis.

P2860

Q21132280-D355F2CD-F50F-4A23-8870-562FD86709D9 Q26745905-749A3AFD-296B-4380-BC76-D01661B5DE5E Q26783055-2CCB4225-B249-40C7-B744-4003198A4D9C Q26852807-651BC460-684B-4298-8F8A-43AFEA88E319 Q26863622-8296B0EE-8A49-45FB-85AF-84F7E107F8FE Q28387396-9E09513A-8A30-4966-B017-C5FE17DD73EA Q28390433-F36BE6C3-C7DF-4ACC-9CD7-4A55DA6FFA58 Q28544930-E1C88D41-18E5-45B0-8DA1-23080869EC7B Q30009050-D4F84253-DC29-4BD9-A153-79049F88167D Q30242020-211C58F6-E30F-4448-8975-CE22C44E172C Q30359234-3E0AF9AB-1CFB-4DCE-A626-9B26DECA4E28 Q30393703-56B12D54-9C26-4539-B4BB-2A9270D631B8 Q30832988-46E8C3C0-91EC-40A2-B3B8-926655CDD633 Q30846907-1BC28BCF-9E0D-48FE-A448-FCD5ACC26989 Q31012806-E518BFF0-3F4F-4447-A6AF-8091A80DD48A Q31125908-29D63AE7-89FF-418E-9DA6-6EA2356103BB Q33655771-0FB3FD12-E831-4670-8914-07FF89FE4AA4 Q33699594-58E5380B-AFE5-4719-977A-099B8CB16D2A Q33851540-9BE620F8-EA23-4E11-B2C5-A02DDF4C9381 Q33977022-CF44CB5E-436A-4505-A087-DA4DAB7FB099 Q34008793-DFA9A62F-DDD0-4E89-97BE-BA67C85B55C1 Q34123603-92412C10-E429-403A-9688-A4ED953688FE Q34295621-B18B00AD-DF4E-48E7-B3F4-9C56226050D6 Q34423170-8264116D-3B3A-444B-9736-73835B3A88BF Q34608734-51BDA0CA-AA9F-4461-9119-63EA10CBAAE0 Q35061942-6681C0E3-6063-4A7D-B16C-E47D8F7FD185 Q35291231-AB244355-A6A6-465F-B392-52504BD983F5 Q35532215-8300A36F-AE06-4FFC-9BA2-84DAAF62440D Q35771700-F19C9E6A-6D53-4877-84BD-C20367CB5439 Q35798726-2E43475A-B7B4-4444-B0BF-ACB1B45A4D6F Q35983341-BE2481B9-A222-4E7F-B347-5DD16C5605AA Q36181146-9880A1C8-31C8-46F7-A945-345FB6578396 Q36210404-5585B312-E5C7-46C6-868C-B82C707C4CFF Q36430991-55CC45A0-DC18-4674-BA80-A29A2CEC44F1 Q36534696-C04CD879-8767-4AB0-B29D-AC56F023424A Q36559818-797829F9-C270-4FC8-950A-7F574180BF34 Q37080936-562B4F3C-4E1F-4052-AEFD-F7903C555353 Q37404690-378F923A-48C3-4F40-840D-03829332244B Q37642504-C6A38C75-B10F-48AA-90F5-22ABF445BC88 Q37737860-EAF365CA-ED64-431B-AC69-FE03F38160EC

P2860

Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance

http://www.wikidata.org/entity/Q26866517

description

2013 nî lūn-bûn

@nan

2013 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մարտին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Personalized cancer medicine: ...... iomarkers, and drug resistance

@ast

Personalized cancer medicine: ...... iomarkers, and drug resistance

@en

Personalized cancer medicine: ...... iomarkers, and drug resistance

@nl

type

label

Personalized cancer medicine: ...... iomarkers, and drug resistance

@ast

Personalized cancer medicine: ...... iomarkers, and drug resistance

@en

Personalized cancer medicine: ...... iomarkers, and drug resistance

@nl

prefLabel

Personalized cancer medicine: ...... iomarkers, and drug resistance

@ast

Personalized cancer medicine: ...... iomarkers, and drug resistance

@en

Personalized cancer medicine: ...... iomarkers, and drug resistance

@nl

P1433

Q26866517-258B327F-7141-413D-8DC9-ACBF50E8BDAC

P1476

Q26866517-322489EC-B852-4A90-B6E9-4FEDCD0933CD

P2093

Q26866517-116E6C65-32F8-4F2D-8E36-3F33464E7FA5

Q26866517-95259C86-0275-4F25-B791-F4180BC7C8EB

Q26866517-AB2DB929-F939-43A0-BCD1-BF6B6FF7673C

P275

Q26866517-6CBEE425-E755-4BD9-8918-0D44EA98A423

P2860

Q26866517-08E97AD0-A062-4F26-8A54-DF628EF79FA1

Q26866517-096B77DB-7563-4DCE-801B-4BA4BBDA258E

Q26866517-0BF94D12-FCA6-4BFF-ADA8-930220BB6B45

Q26866517-10E2C731-EACA-4A49-92C2-64763591CF12

Q26866517-18E620A7-4F68-451C-8E2A-6D7AE239BA76

Q26866517-1C6CABC1-ECB3-413C-BEF1-E6BA777115EA

Q26866517-1CE772BF-21EC-4678-8850-6D6668276628

Q26866517-1E033127-977F-422E-AFC4-938B7833D27C

Q26866517-213F3E64-72D7-4B6D-A36C-BE4B287A8C95

Q26866517-237924EA-C209-433D-AAEB-263962ADB864

P2888

Q26866517-AB80AC9B-2747-4EA4-B2EE-E35A1C50787F

P304

Q26866517-166984E0-79E1-40D5-AA37-360A47AC8837

P31

Q26866517-22B0D1B0-2D2E-4054-91CA-3071F4844FB0

Q26866517-33F99EC4-F304-47E5-B9D9-7D3CC9E2865A

P3181

Q26866517-C67469DB-37E6-495E-8623-549CDD5AA7B1

P356

Q26866517-5D2E7C5A-13C5-4768-B1C3-62EDC4FC8A00

P407

Q26866517-D85D92C1-DDC9-470A-BE2D-8D9058FD4130

P433

Q26866517-5D4D17E2-37BF-45B4-92FB-9E9BDB7A9DC6

P478

Q26866517-4BAD1867-B7DD-412E-9B5C-5AF296861BBA

P50

Q26866517-4CEC98C4-18BC-4C9E-BBC1-0B0CDE281B23

P5008

Q26866517-F594F246-C645-4CFC-A84F-DA7B789A8917

P577

Q26866517-023CC58F-B165-4FF2-AD27-F8CB4C618BE1

Q26866517-1DBF93BC-42BC-44E4-AEE4-771BD71D6747

P5875

Q26866517-52D27649-E37C-405A-9219-ECA6841D32B7

P6179

Q26866517-7C751BB2-83FD-4140-9C9B-F1256EDB46D0

P698

Q26866517-EF78E184-FC66-4A33-B561-1B4292F1353C

P921

Q26866517-61769EF7-55E0-447A-856A-2182C1E1FD8E

Q26866517-7EE6B4AA-06C2-4434-9A7F-3DF68FC98D7F

Q26866517-909426CD-306B-4E3A-95F9-F3894A89C76C

Q26866517-D9DD4959-0327-42BB-8796-623CF65E8A4F

P932

Q26866517-5DBE989D-2F5A-486B-B507-BE3067040CD7

P3181

P356

P1433

Clinical Pharmacology & Therapeutics

P1476

Personalized cancer medicine: ...... iomarkers, and drug resistance

@en

P2093

D Gonzalez de Castro

http://www.w3.org/2001/XMLSchema#string

P A Clarke

http://www.w3.org/2001/XMLSchema#string

P Workman

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

A census of human cancer genes

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

P2888

P304

252-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1174196

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/CLPT.2012.237

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

93

http://www.w3.org/2001/XMLSchema#string

P50

Bissan Al-Lazikani

P5008

P577

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235382454

http://www.w3.org/2001/XMLSchema#string

P6179

1022698279

http://www.w3.org/2001/XMLSchema#string

P698

23361103

http://www.w3.org/2001/XMLSchema#string

P921

tumor biomarkers

physiological phenomena

P932

3577635

http://www.w3.org/2001/XMLSchema#string